to analyze the association of asthma and CVD. We hypothesized that persistent asthma is associated with higher CVD risk in the Multi-Ethnic Study of Atherosclerosis (MESA).
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Descriptive Characteristics
The 6792 MESA participants were followed up for a mean (SD) 9.1 (2.8) years for development of CVD. At baseline, participants were 62.2 (10.3) years old, and 47.1% were men, 38.4% were whites, 27.8% blacks, 22.0% Hispanic, and 11.8% Chinese ( Table 1 ). The 156 participants with persistent asthma and the 511 participants with intermittent asthma were compared with the 6125 participants without asthma.
The distribution of risk factors between those with persistent asthma and those with intermittent asthma differed slightly compared with those without asthma (Table 1) . Those with asthma were more likely to be women (64% versus 52%) and on antihypertensive medications (41% versus 37%).
Asthma and Cardiovascular Events
A total of 642 CVD events (249 hard end point coronary heart disease events, 188 angina, 167 stroke, 3 stroke deaths, and 35 CVD deaths) occurred during the observation period. The incidence rate for CVD was higher in those with persistent asthma. The 10-year CVD-free survival rates were 89.5% (95% confidence interval [CI], 87.0%-91.9%) for those with asthma and 90.2% (89.4%-91.0%) for those who did not report a diagnosis of asthma. Among those with asthma, the 10-year CVD-free survival rates were 84.1% (78.4%-90.3%) for those with persistent asthma and 91.1% (88.5%-93.8%) for those with intermittent asthma. In multivariate models adjusted for potential confounders, having persistent asthma was associated with a significantly higher risk of CVD events. In models adjusted for age, race, and sex ( 
Asthma and Inflammatory Biomarkers
Inflammatory markers were analyzed to assess the burden of systemic inflammation between the groups with persistent asthma, intermittent asthma, and those without asthma. Those with persistent asthma had the highest levels of systemic inflammatory markers (Table 3 ). Persistent asthmatics, compared with intermittent asthmatics and nonasthmatics, respectively, had higher age-adjusted levels of C-reactive protein (CRP: [73] mg/dL) mean differences were significant using Tukey criteria. Interleukin-6 levels were the highest in persistent asthmatics 0.44 (0.61) compared with intermittent asthmatics 0.25 (0.67) and no asthma 0.20 (0.66; Table 3 ). When CRP and d-dimer were added to the a priori fully adjusted model, they were not statistically significant predictors of CVD outcomes and did not attenuate the asthma effect. When added to these models, interleukin-6 and fibrinogen were statistically significant predictors of CVD outcomes but did not notably attenuate the asthma effect (the HR was 1.55-1.59 in all models).
Discussion
After a decade of prospective observation, persistent asthmatics had a 1.6-fold higher risk of CVD events than nonasthmatics in models fully adjusted for potential confounders. Despite being treated for their asthma, persistent asthmatics on controller medications had the highest burden of systemic inflammation. To our knowledge, our study represents the largest contemporary, multiethnic, long-term, prospective cohort to analyze the association of asthma and CVD. Previous studies investigating the association between asthma and CVD have been limited by case-control and cross-sectional designs, studied retrospective insurance claims, or contained a homogenous group of individuals with older asthma treatments. [11] [12] [13] [14] [15] [16] [17] [18] Furthermore, some studies noted no association between asthma and CVD or described limited associations of women only or associations only with stroke. 12, 15, 17 Two previous reports from the population-based Atherosclerosis Risk in Communities (ARIC) study cohort investigated the association of asthma with incident CVD. In the first report, there was an association of stroke with asthma with a higher risk in women but no association with coronary heart disease. 12 In the second, there was an association of coronary heart disease and stroke among women with adult-onset asthma but not men. 18 We observed an association of persistent asthmatics, but not intermittent asthmatics, with CVD events.
Our study results and design differ from the previous studies in several ways. First, we did not observe effect modification by female sex. 11, 14, 18 The 3 investigations that observed effect modification by sex had more participants, but 2 used insurance claims databases and the other, a report from the ARIC study, was discussed above. Our study may not have had enough statistical power to identify effect modification by sex. 11, 14, 18 Second, a strength of our article is that we accounted for the heterogeneous nature of asthma and classified it by severity (intermittent versus persistent). Thus, our clinical classification of asthma was different from that of previous studies 11, 14, 18 and was validated by its association with serum inflammatory markers. Third, other studies had limited data on systemic markers of inflammation; only one study demonstrated that women with adult-onset asthma had higher fibrinogen levels. 18 Previous population-based studies have demonstrated a positive association between asthma severity and levels of systemic inflammatory markers, such as hs-CRP and fibrinogen levels. 17, 19 Our data demonstrated graded relationships between inflammatory markers, asthma classification. Finally, our study was contemporary and included large numbers of ethnic minorities. There is a higher prevalence of asthma among ethnic minorities, and there have been significant changes in asthma treatment and CVD prevention during the antecedent 2 decades. Inhaled corticosteroids currently are the mainstay of therapy for asthma management, and statins reduce CVD risk.
MESA is a prospective cohort study of participants enrolled from 2000 to 2002 and followed through 2012, all of which were free of CVD at baseline with the purpose of investigating the development and progression of subclinical atherosclerosis. We observed a longitudinal association of persistent asthma and CVD events in a contemporary, multiethnic cohort with adjustment for traditional risk factors and additional adjustment for statin and antihypertensive medication use. The most recent investigation that analyzed the association of asthma and CVD was from the Kaiser Permanente Northern California healthcare claims database. It demonstrated an increased risk of CVD events among asthmatics with a similar HR to our finding with stronger associations for those on asthma medications and in women. 14 In contrast to the Kaiser Permanente analysis that used International Classification of Diseases, Ninth Revision codes to identify CVD events, all CVD events in MESA were adjudicated. This is especially important because asthma exacerbations need to be accurately distinguished from heart failure events. Because of their overlap in clinical presentations, we did not include heart failure as an end point in this study to avoid misclassification bias. Also, claims databases do not have patient-level laboratory, physical examination, and medical or family history information. Some use proxy measures to adjust for potential biological confounders, such as using International Classification of Diseases, Ninth Revision codes, which can increase residual confounding. Because these codes are primarily used for billing purposes, they are prone to upcoding to more severe conditions, such as heart failure, for higher reimbursement. 20 Finally, given the breadth of data collected in MESA, we were able to adjust for additional potential risk factor and sociodemographic confounders of the association between asthma and CVD. Despite the differences in study design, the current investigation found a similar magnitude of association between asthma and CVD events in fully adjusted models compared with the Kaiser Permanente claims database study; however, in this study, we did not see effect modification by female sex.
Asthma and CVD share an inflammatory pathogenesis. Although there are differences in the inflammatory pathophysiologies between these 2 conditions, data from animal models suggest that there may be significant overlap. Inflammation in asthma is partly mediated through the 5-lipo-oxygenase enzymatic pathway. In this pathway, 5-lipo-oxygenase catalyzes conversion of arachidonic acid leading to the formation of leukotriene A4 that can then be converted into 1 of 4 different leukotrienes. Leukotrienes are paracrine inflammatory substances produced in immune cells that induce both acute and chronic inflammation. 21 In bronchioles, leukotrienes act as potent smooth muscle constrictors, induce tissue edema, and are signals for migration of eosinophils. Atherosclerotic plaques also express 5-lipo-oxygenase and contain elevated levels of leukotrienes. 10 In animal models, blockade of leukotriene B4 results in less monocyte recruitment and a reduction in atheroma progression. 9 The 5-lipo-oxygenase pathway also has been implicated in CVD events as increased levels of 5-lipo-oxygenase, and leukotrienes have been associated with plaque instability. 21, 22 Systemic inflammation that increases the risk of a CVD event may also affect asthma control. Additional studies have found associations between hs-CRP, airway hyper-responsiveness, and forced expiratory volume in 1 s among individuals free of CVD, suggesting that systemic inflammation also effects lung function. 23 High-sensitivity CRP levels also have been used as a surrogate marker of disease control in asthmatics, with lower levels indicating better disease control. 24 In MESA, participants with persistent asthma had the highest level of systemic inflammatory markers. Furthermore, there was a graded relationship between those without asthma having the lowest levels of inflammation, those with intermittent asthma having intermediate levels, and those with persistent asthma having the highest levels of inflammatory markers. Previous studies have demonstrated that treatment of asthma with anti-inflammatory medications, such as inhaled corticosteroids, results in lower levels of markers of systemic inflammation. 25, 26 The identification of elevated inflammatory markers among participants with persistent asthma in our study is hypothesis-generating; however, we note that their addition to the models did not attenuate the relationship between persistent asthma and CVD events; so, we cannot imply a mediated effect. This may be because of partial treatment of inflammation by controller medications. It is also possible that asthma medications have adverse CVD effects via their effects on glucocorticoid metabolism, lipid metabolism, or in the case of long-acting β-antagonists, sympathetic activation. The elevated levels of systemic inflammatory markers observed among persistent asthmatics may have contributed to the increased CVD risk in this group; however, further studies are needed to elucidate this mechanism.
Limitations
Despite the numerous strengths of this study, there are some limitations. As an observational study, the described associations do not confirm causation. Asthma was defined by selfreport and may be prone to misclassification bias, although we classified participants by use or nonuse of controller medications to improve the specificity of the diagnosis. We did not have lung function parameters at the baseline examination, and given the heterogeneous nature of asthma severity, according to current guidelines, we defined the use of controller medications as an indicator of more severe disease. 27 The graded levels of inflammatory markers among the asthma classifications in this report support our approach, as those using controller medications had more systemic inflammation, and if anything, misclassification should lead to a null bias. The primary hypothesis of this study was to investigate the association between persistent asthma and CVD events. Given the design of MESA, this study cannot delineate the mechanism that led to higher CVD rates. Although we treated the use of controller medications as a marker of more severe asthma and that supposition was supported by our biomarker data, we cannot exclude the possibility that controller or other asthma medications increased CVD risk. Certain classes of controller medications have been associated with CVD risk, especially among individuals with chronic obstructive pulmonary disease; however, these associations have been inconsistent and a few studies have noted a reduction in CVD events with the use of inhaled corticosteroids. [28] [29] [30] Regression models were adjusted for measured risk factor and sociodemographic variables; however, unmeasured lifestyle exposures and risk factors that may be specific to each ethnicity cannot be accounted for. MESA is a United States cohort; so, the generalizability of these findings to populations outside the United States may be limited. The small number of CVD events limited our power to detect potential effect modification by sex or race. Finally, asthma is a heterogeneous disease that has complex genetic and environmental factors; thus, generalizability to all subtypes is uncertain. To disentangle the limitations of observational studies, such as MESA, it would be useful if the large, randomized clinical trials of asthma medications had longer durations, measured inflammatory biomarkers, and formally adjudicated CVD events.
Conclusions
Persistent asthmatics taking daily controller medications were at increased risk of CVD events. Persistent asthmatics demonstrated higher levels of systemic inflammation than nonasthmatics or intermittent asthmatics. Given the increasing public health burden of asthma and the pathophysiological overlap of asthma and CVD, further investigations into this association are needed.
